Key result
The modified metabolic syndrome in patients undergoing noncardiac surgery was associated with a higher risk of 30-day mortality (AOR 1.99 for super obese) compared with normal-weight patients.
Why the study?
Does the modified metabolic syndrome increase the risk of 30-day mortality and complications in patients undergoing noncardiac surgery?
Observational (n=310,208)
Yes
Does the modified metabolic syndrome increase the risk of 30-day mortality and complications in patients undergoing noncardiac surgery?
Patients with modified metabolic syndrome undergoing noncardiac surgery have a substantially higher risk of 30-day mortality, cardiac adverse events, and acute kidney injury compared to normal-weight patients, challenging the obesity paradox in this specific subgroup.
Answers are grounded in this paper and cite their sources.
Should not yet change perioperative practice; extends evidence challenging the obesity paradox in observational surgical cohorts.
BACKGROUND: Previous studies have demonstrated that obesity is paradoxically associated with a lower risk of mortality after noncardiac surgery. This study will determine the impact of the modified metabolic syndrome (defined as the presence of obesity, hypertension, and diabetes) on perioperative outcomes. METHODS: This study is based on data from 310,208 patients in the American College of Surgeons National Surgical Quality Improvement Program database. We estimated separate multivariate logistic regression models for 30-day mortality and for 30-day complications. RESULTS: Patients with the modified metabolic syndrome who are super obese had a 2-fold increased risk of death (adjusted odds ratio [AOR] 1.99; 95% CI 1.41-2.80). As stratified by body mass index, patients with the modified metabolic syndrome had a 2- to 2.5-fold higher risk of cardiac adverse events (CAE) compared with normal-weight patients: obese (AOR 1.70; 95% CI 1.40-2.07), morbidly obese (AOR 2.01; 95% CI 1.48-2.73), and super obese (AOR 2.66; 95% CI 1.68-4.19). In addition, the risk of acute kidney injury (AKI) was 3- to 7-fold higher in these patients: obese (AOR 3.30; 95% CI 2.75-3.94), morbidly obese (AOR 5.01; 95% CI 3.87-6.49), and super obese (AOR 7.29; 95% CI 5.27-10.1). CONCLUSION: Patients with the modified metabolic syndrome undergoing noncardiac surgery are at substantially higher risk of complications compared with patients of normal weight.
No takes yet. Share an insight, caveat, or question.
Glance et al. (2010) conducted an observational in Modified metabolic syndrome in noncardiac surgery (n=310,208). Modified metabolic syndrome vs. Normal-weight patients was evaluated on 30-day mortality (AOR 1.99, 95% CI 1.41-2.80). The modified metabolic syndrome in patients undergoing noncardiac surgery was associated with a higher risk of 30-day mortality (AOR 1.99 for super obese) compared with normal-weight patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: